All AbMole products are for research use only, cannot be used for human consumption.
Brivanib (BMS-540215) is an ATP-competitive inhibitor of human VEGFR -2, with an IC50 of 25 nmol/L and Ki of 26 nmol/L. Brivanib is currently in development for the treatment of hepatocellular and colon carcinomas. In vitro and in vivo studies were conducted to characterize the preclinical pharmacokinetics and disposition of brivanib and brivanib alaninate, and antitumor efficacy in mice bearing human xenografts.
 |
Source | AJR Am J Roentgenol (2014). Figure 3. Brivanib |
| Method | DCE-MRI | |
| Cell Lines | HepG2 cells | |
| Concentrations | 0.01 mL/g | |
| Incubation Time | 14 d | |
| Results | In the brivanib-treated group, the Ktrans and ve values decreased statistically significantly between baseline and 7 days after treatment (p = 0.024 and p = 0.031, respectively), and between baseline and 14 days after treatment (p = 0.043 and p = 0.018), and did not show statistically significant changes between 7 days and 14 days (p = 0.302 and p = 1, respectively). |
 |
Source | AJR Am J Roentgenol (2014). Figure 2. Brivanib |
| Method | DCE-MRI | |
| Cell Lines | HepG2 cells | |
| Concentrations | 0.01 mL/g | |
| Incubation Time | 14 d | |
| Results | The mean MVD in the tumors that were treated with vehicle and brivanib was approximately 55.2 ± 9.5 vessels/field and 40.8 ± 17.3 vessels/field, respectively (Fig. 2). |
| Cell Experiment | |
|---|---|
| Cell lines | VEGF or FGF stimulated HUVECs |
| Preparation method | The cells are stimulated by VEGF or FGF at a concentration of 8 or 80 ng/mL. These cells are seeded in 96 well plates at a density of 2 × 103 and incubated for 24 hours. Brivanib at various dilutions are added to the cells for another 48 hours. Then 0.5 μCi of [3H] thymidine is added for 24 hours. After that the incorporated tritium is quantified using a β-counter. |
| Concentrations | ~ 10 μM |
| Incubation time | 48 hours |
| Animal Experiment | |
|---|---|
| Animal models | H3396 xenografts in athymic mice |
| Formulation | Dissolved in PEG400: Tween80 (75:25) (orally) or PEG400: water (3:2) (intravenously) |
| Dosages | 60 mg/kg (orally) or 10 mg/kg (intravenously) |
| Administration | oral or i.v. |
| Molecular Weight | 370.38 |
| Formula | C19H19FN4O3 |
| CAS Number | 649735-46-6 |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related VEGFR/PDGFR Products |
|---|
| ABT-869
ABT-869 (Linifanib) is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of VEGFR and PDGFR. |
| Tivozanib (AV-951)
Tivozanib (AV-951) is a potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM respectively. |
| Axitinib
Axitinib (AG013736) inhibits multiple targets including VEGFR, PDGFR and cKit. |
| Regorafenib
Regorafenib (BAY 73-4506) is a novel oral multikinase inhibitor of c-KIT, VEGFR2, B-Raf with IC50s of 17, 40 and 69 nM respectively. |
| Nintedanib
Nintedanib (BIBF1120) is a novel, potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
